

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

CANCELLATION OF SHARE OPTIONS UNDER THE 2022 SHARE OPTIONS INCENTIVE SCHEME

Reference is made to the announcements of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 August 2022, 21 September 2022, 7 November 2022, 23 November 2022, 30 October 2023 and 29 November 2023, and the circular of the Company dated 27 September 2022 (the “**Circular**”) in relation to, among others, the proposed adoption of the 2022 Share Options Incentive Scheme (Revised Draft) (the “**Incentive Scheme**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

According to the relevant provisions of the Incentive Scheme and the “2023 Annual Audit Report” of the Company, the performance targets at the Company level for the second exercise period of the Share Options under the First Grant and the first exercise period of the Share Options under the Reserved Grant were not met. Therefore, the 5,283,750 Share Options corresponding to the second exercise period of the Share Options under the First Grant and the 1,000,000 Share Options corresponding to the first exercise period of the Share Options under the Reserved Grant shall not be exercised and shall be canceled by the Company.

Upon completion of the cancellation, the remaining number of Share Options under the First Grant will be 7,806,930 and the remaining number of Share Options under the Reserved Grant will be 1,000,000.

By order of the Board
Livzon Pharmaceutical Group Inc. *
麗珠醫藥集團股份有限公司
Yang Liang
Company Secretary

Zhuhai, China
13 May 2024

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*